UPDATE: Valeant Pharmaceuticals Posts Upbeat Q4 Profit
Canada's Valeant Pharmaceuticals International Inc (NYSE: VRX) posted a fourth-quarter profit.
Valeant Pharmaceuticals posted a quarterly net income at $55.9 million, or $0.18 per share, versus a year-ago net loss of $31.1 million, or $0.10 per share. Its revenue climbed 34% to $688.5 million. Its adjusted cash income came in at $297.7 million, or $0.94 per share.
Analysts were expecting earnings of $0.85 per share.
VRX shares closed at $47.93 on Friday.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.